Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Name:
Andronis_et_al-2016-BJU_Intern ...
Size:
200.6Kb
Format:
PDF
Description:
Open access full text article
Authors
Andronis, LGoranitis, I
Pirrie, S
Pope, A
Barton, D
Collins, S
Daunton, A
McLaren, D
O'Sullivan, J
Parker, C
Porfiri, E
Staffurth, J
Stanley, A
Wylie, James P
Beesley, S
Birtle, A
Brown, J
Chakraborti, P
Hussain, S
Russell, J
Billingham, L
James, N
Affiliation
Health Economics Unit, University of Birmingham, UKIssue Date
2016-06-03
Metadata
Show full item recordAbstract
To evaluate the cost-effectiveness of adding zoledronic acid or strontium-89 to standard docetaxel chemotherapy for patients with castrate-refractory prostate cancer (CRPC).Citation
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). 2016: BJU IntJournal
BJU InternationalDOI
10.1111/bju.13549PubMed ID
27256016Type
ArticleLanguage
enISSN
1464-410Xae974a485f413a2113503eed53cd6c53
10.1111/bju.13549
Scopus Count
Collections
Related articles
- TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
- Authors: James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, Collins S, McLaren D, O'Sullivan J, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown J, Chakraborti P, Russell M, Billingham L
- Issue date: 2016 Jul
- Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
- Authors: James ND, Pirrie SJ, Pope AM, Barton D, Andronis L, Goranitis I, Collins S, Daunton A, McLaren D, O'Sullivan J, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown J, Chakraborti P, Hussain S, Russell M, Billingham LJ
- Issue date: 2016 Apr
- Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
- Authors: Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW
- Issue date: 2011 Oct
- Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
- Authors: Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K
- Issue date: 2012
- Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
- Authors: McKeage K, Plosker GL
- Issue date: 2008